Ulcus-Therapie pp 137-154 | Cite as

Andere Sekretionshemmer und Medikamente zur Förderung der Schleimhautresistenz

  • W.-P. Fritsch
Conference paper
Part of the Interdisziplinäre Gastroenterologie book series (GASTROENTEROLOG)

Zusammenfassung

Die Gruppe dieser Substanzen zeichnet sich vorwiegend durch eine Hemmung der Säure- und/oder Pepsinsekretion aus. Die häufig gleichzeitig zu beobachtende Hemmung der Sekretion von Intrinsicfactor gilt als eine unerwünschte Nebenwirkung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Archambault, A., Farley, A., Gosselin, D., Martin, F.: Multicentre double-blind study of duogastrone in the treatment of duodenal ulcers. Fourth Symposium on Carbenoxolone. Jones, F. A., Parke, D. V. (eds.), pp. 251–254. London: Butterworths 1975Google Scholar
  2. 2.
    Asano,T.: Study of gastric blood flow. VI. Congress Ther. Res. New Drugs. Osaka 1969, Rep. Vol., pp. 108–122Google Scholar
  3. 3.
    Bianchi Porro, G., Ferrara, A., Petrillo, M., Abbondati, G.: Attività inibitrice della tritiozina (ISF2001) e della propantelina sulla secrezione gastrica nell’uomo. Studio cross-over in doppio cieco. Minerva Gastroent. 22, 149–152 (1976)Google Scholar
  4. 4.
    Cocking, J.B., McCaig, J.B.: Effect of low dosage of carbenoxolone sodium on gastric ulcer healing and acid secretion. Gut 10, 219–225 (1969)PubMedCrossRefGoogle Scholar
  5. 5.
    Collyns, A.H., Fordtran, J.S.: Controlled analysis of antacids and anticholinergics in modifying gastric acidity and peptic activity after steak in patients with duodenal ulcer. Gastroenterology 48, 812 (1965)Google Scholar
  6. 6.
    Corinaldesi, R., Luchetta, R., Miglioli, M., Ricci, P., Casadio, R., Barbara, L.: Effetti su secrezione e motilità gastrica nell’uomo della 4-(3,4,5-trimetossitio-benzoil) tetraidro- 1,4-ossazina (tritiozina). Atti XX Congr. Naz. Soc. Gastroent. Rendicont. di Gastroenterologia 7, 22–25(1975)Google Scholar
  7. 7.
    Cornet, A., Grivaux, M.: Recherches physiopathologiques sur le sulpiride en gastroenterologie. Bull. Mém. Soc. Méd. Hòp. 119, 753–760 (1968)Google Scholar
  8. 8.
    Doll, R., Hill, I.D., Hutton, C.F.: Treatment of gastric ulcer with carbenoxolone sodium and oestrogen. Gut 6, 10–24 (1965)CrossRefGoogle Scholar
  9. 9.
    Doll, R., Hill, I.D., Hutton, C., Underwood, D.J.: Clinical trial of a triterpenoid liquorice compound in gastric and duodenal ulcer. Lancet 1962 II, 793–796CrossRefGoogle Scholar
  10. 10.
    Domschke, W., Domschke, S., Classen, M., Demling, L.: Bedeutung der N-Acetylneuraminsäure im Magensaft - ein therapeutischer Aspekt. In: Das peptische Ulcus. Demling, L. (Hrsg.), S. 105–111. Stuttgart: Schattauer 1973Google Scholar
  11. 11.
    Dotevall, G.: Comment. Selected summaries. Gastroenterology 60, 1142–1143 (1971)Google Scholar
  12. 12.
    Dotevall, G., Schröder, G., Walan, A.: The effect of poldine, glycopyriolate, and 1-hyoscyamine on gastric secretion of acid in man. Acta med. scand. 177, 169–174 (1965)PubMedCrossRefGoogle Scholar
  13. 13.
    Einig, D.: Ein neuer Sekretionshemmer: Ergebnisse einer Wirkungs- und Verträglichkeitsprüfung mit Gastrozepin. Therapiewoche 27, 1630–1638 (1977)Google Scholar
  14. 14.
    Feldmann, H., Gilat, T.: A trial of deglycyrrhizinated liquorice in the treatment of duodenal ulcer. Gut 12, 449–451 (1971)CrossRefGoogle Scholar
  15. 15.
    Feldman, M., Richardson, C.T., Peterson, W.L., Walsh, J.H., Fordtran, D.S.: Effect of low-dose propantheline on food-stimulated acid secretion. N. Eng. J. Med. 297, 1427- 1430(1977)CrossRefGoogle Scholar
  16. 16.
    Fritsch, W.-P., Schacht, U., Schölten, Th., Jäger, N., Hengels, K.-J., Müller, J., Strasser, K.: Cimetidinwirkung auf die durch intraoperativen elektrischen Vagusreiz freigesetzte H-Sekretion bei Patienten mit Ulcus duodeni. Verh. Dtsch. Ges. inn. Med.84, 1978 (in Druck)Google Scholar
  17. 17.
    Gibinski, K., Rybicka, J., Mikos, E., Nowak, A.: Double-blind clinical trial on gastro- duodenal ulcer healing with prostaglandin E2 analogues. Gut 18. 636–639 (1977)PubMedCrossRefGoogle Scholar
  18. 18.
    Hammer, R., Bozler, G., Zimmer, A., Koss, F.W.: Pharmakokinetik und Metabolismus von LS 519-CI2 (Pirenzepin) beim Menschen. Therapiewoche 27, 1575–1593 (1977)Google Scholar
  19. 19.
    Hammer, R., Kaubisch, N., Kopitar, Z., Prox, A., Zimmer, A., Koss, F.W.: Untersuchungen zu Pharmakokinetik und Metabolismus von LS 519-C12 (Pirenzepin) an Ratte, Kaninchen und Hund. Therapiewoche 27, 1567–1574 (1977)Google Scholar
  20. 20.
    Hausamen, T.-U., Fritsch, W.-P.: Physiologie und Pathophysiologie gastrointestinaler Hormone der Gastrin- und Sekretingruppe. Teil II: Cholezytokinin-Pankreozymin und Sekretingruppe. Z. Gastroent. 15, 320–336 (1977)Google Scholar
  21. 21.
    Hausamen, T.-U., Fritsch, W.-P., Schölten, Th., Jungblut, R. M., Strohmeyer, G.: Behandlung peptischer Ulcera beim Zollinger-Ellison-Syndrom mit Histamin-h2-Rezeptor-Antagonisten. Dtsch. med. Wschr. 102, 1709–1712 (1977)PubMedCrossRefGoogle Scholar
  22. 22.
    Horwich, L., Galloway, R.: Treatment of gastric ulceration with carbenoxolone sodium: clinical and radiological evaluation. Brit. med. J. 1976 11, 1274–1277Google Scholar
  23. 23.
    Hoskins, E.O.L.: Metoclopramide in benigne gastric ulceration. Postgrad, med. J. 49 (Suppl.4), 95–97 (1973)Google Scholar
  24. 24.
    Hunt, T., Abrains, M., Atkinson, M.: Carbenoxolone in the treatment of duodenal ulcer. A multicentre trial. Brit. J. din. Pract. 27,50–55 (1973)Google Scholar
  25. 25.
    Innes, I.R., Nickerson, M.: Drugs inhibiting the action of acetylcholine on structures innervated by postganglionic parasympathetic nerves. Antimuscarinic or atropinic drugs. In: The pharmacological basis of therapeutics, 3rd. Ed. Goodman, L.S., Gilman, A. (eds.), pp. 521–545. New York: Macmülan 1965Google Scholar
  26. 26.
    Kaye, M.D.: Anticholinergic drugs in duodenal ulcer. Gastroenterology 62, 502–504 (1972)PubMedGoogle Scholar
  27. 27.
    Koelz, H. R., Fischer, J., Sachs, G., Blum, A. L.: A specific action of aspirin on gastric cell membrane. Gastroenterology 72, 1059/1082 (1977)Google Scholar
  28. 28.
    Konturek, S. J., Kwiencien, N., Swierczek, J., Oleksy, J., Sito, E., Robert, A.: Comparison of methylated prostaglandin E2 analogues given orally in the inhibition of gastric responses to pentagastrin and peptone meal in man. Gastroenterology 70, 683–687 (1976)PubMedGoogle Scholar
  29. 29.
    Leading article: Anticholinergics and duodenal ulcer. Lancet 1973 II, 1173Google Scholar
  30. 30.
    Mahl, G.F.: Anxiety, HCl-Secretion, and peptic ulcer etiology. Psychosom. Med. 12, 158–169(1950)PubMedGoogle Scholar
  31. 31.
    Margolin, S. G.: The behavior of the stomach during psychoanalysis. A contribution to a method of verifying psychoanalytic data. Psychoanalytic Quart. 20, 349–357 (1951)Google Scholar
  32. 32.
    Masuda, M.: Results of a national scale statistical study of a double blind study. VI. Congress Ther. Res. New Drugs, Osaka 1969, Rep. Vol. 1–20Google Scholar
  33. 33.
    Middleton, W.R.J., Cooke, A. R., Stephen, D., Skyring, A. P.: Biogastrone in inpatient treatment of gastric ulcer. Lancet19651, 1030–1032Google Scholar
  34. 34.
    Misiewicz, J.J., Russell, R. I., Baron, J.H.: Treatment of duodenal ulcer with glycyrrhizinic-acid-reduced liquorice. A multicentre trial. Brit. med. J. 3, 501–503 (1971)Google Scholar
  35. 35.
    Mitchell, R.D., Hunt, J. W., Grossman, M.L: Inhibition of basal and postprandial gastric secretion by poldine and atropine in patients with peptic ulcer. Gastroenterology 43,400–406(1962)Google Scholar
  36. 36.
    Molle, M.: Sulpirid bei der’Behandlung von Gastroduodenalgeschwüren. Fortschr. Med. 93, 1077–1082(1975)PubMedGoogle Scholar
  37. 37.
    Nagy, G.S.: Evaluation of carbenoxolon sodium in the treatment of duodenal ulcer. Gastroenterology 74, 7–10 (1978)PubMedGoogle Scholar
  38. 38.
    Newman, A., Pradc, J., DeMoreas-Filho, P., et al.: The effect of intravenous infusion of prostaglandins E2 and F2 on human gastric function. Gut 16, 272–276 (1975)PubMedCrossRefGoogle Scholar
  39. 39.
    Ottenjann, R., Rösch, W.: Clinical and experimental studies on carbenoxolon sodium. In: Carbenoxolon sodium. Baron, J.H., Sullivan, F.M. (eds.), pp. 75–79. London: Butterworths 1970Google Scholar
  40. 40.
    Pürckhauer, V.: Gibt es neue Möglichkeiten in der Ulcustherapie? Therapiewoche27, 1643–1649(1977)Google Scholar
  41. 41.
    Scobie, B.A.: Gastric ulcer treatment with carbenoxolone sodium (“Biogastrone”). N. Z. med. J. 65, 308–309(1966)PubMedGoogle Scholar
  42. 42.
    Sun, D.C.H.: Long-term anticholinergic therapy for prevention of recurrence in duodenal ulcer. Amer. J. dig. Dis. 9,706–716 (1964)PubMedCrossRefGoogle Scholar
  43. 43.
    Tewari, S.N., Trembalowicz, P.B.: Some experience with deglycyrrhizinated liquorice in the treatment of gastric and duodenal ulcers with special reference to its spasmolytic effect. Gut 9,48–51 (1968)PubMedCrossRefGoogle Scholar
  44. 44.
    Turpie, A.G.G., Thomson, T.J.: Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side effects. Gut 6, 591–594 (1965)PubMedCrossRefGoogle Scholar
  45. 45.
    Walan, A.: Studies on peptic ulcer disease with special reference to the effect of hyoscyamine. Acta med. scand. 516 (suppl.), 1–57 (1970)Google Scholar
  46. 46.
    Wieck, H.H., Kallenberg, A., Liebler, G., Pauli, W., Posth, H.-E.: Klinische Untersuchungen zur Psychosomatik der Ulcuskrankheit. Neurologie 27, 133–160 (1959)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • W.-P. Fritsch

There are no affiliations available

Personalised recommendations